Kidney Stone Plant (Phyllanthus Niruri): Benefits, Evidence & Safe Use

What is the kidney stone plant? (Phyllanthus niruri / Chanca Piedra)

Phyllanthus niruri, commonly known as “stone breaker” or Chanca Piedra (Spanish for “break stone”), is a tropical herb that grows in the Amazon rainforest and other parts of South America, as well as in India and China. The plant has thin, leaf‑covered branches and produces small green flowers and seed pods that grow beneath the leaves – giving it another name, “seed‑under‑leaf.”

In traditional medicine systems including Ayurveda and Amazonian folk medicine, the entire plant (leaves, stems, and flowers) has been used for over 2,000 years to treat kidney stones, liver disorders, and urinary tract infections. The herb contains various bioactive compounds, including lignans, alkaloids, flavonoids, and tannins, which are thought to be responsible for its medicinal effects.

Traditional use – the “stone breaker” legacy

Phyllanthus niruri has a long history of use in multiple traditional medicine systems:

• Amazonian medicine: Used as a decoction or infusion for kidney stones, gallstones, and as a diuretic.
• Ayurveda: Known as “Bhumi Amla” (although that name can also refer to other Phyllanthus species). Used for jaundice, liver disorders, and urinary stones.
• Traditional Chinese Medicine: Used for similar indications, particularly for conditions related to “dampness” and “heat” in the urinary system.
• Brazilian folk medicine: Called “quebra pedra” (stone breaker), widely used for kidney stones and as an anti‑inflammatory.

The traditional preparation involves boiling the whole plant in water to make a tea, which is consumed several times daily. Today, the herb is available in capsules, tablets, liquid extracts, tinctures, and dried leaf form.

Proposed mechanisms of action (what the science says)

Laboratory and animal studies have identified several potential mechanisms by which Phyllanthus niruri might affect kidney stones. A 2025 systematic review of 16 studies identified the following:

• Promoting glycosaminoglycan (GAG) aggregation: GAGs are natural compounds in urine that coat crystal surfaces and prevent stone formation. P. niruri may enhance their activity.
• Inhibiting nucleation processes: Nucleation is the initial step of crystal formation. P. niruri may interfere with this process, reducing the number of crystals that form.
• Altering stone density: Some research suggests P. niruri may modify the density of residual stone fragments, potentially making them easier to pass.
• Ureteral smooth muscle relaxation: The herb may have a mild spasmolytic effect, similar to tamsulosin, helping stones pass more easily.

Importantly, no mechanism has been identified that would allow P. niruri to dissolve existing calcium oxalate stones. The effect is likely preventive or facilitative, not curative.

Clinical evidence – what studies actually show

Human studies on P. niruri are limited but growing. Here is a summary of the key evidence:

1. As an adjunct to ESWL (shock wave lithotripsy)

A randomised prospective study of 150 patients with renal stones (up to 25mm) found that those who took P. niruri extract (2g daily for 3 months) after ESWL had a stone‑free rate of 93.5% at 180 days, compared to 83.3% in the control group. For lower caliceal stones specifically, the stone‑free rate was 93.7% with P. niruri versus 70.8% without. No side effects were recorded.

2. For medical expulsion therapy (distal ureteral stones)

A 2024 retrospective cohort study of 159 patients with distal ureteral stones (≤10mm) compared tamsulosin alone versus tamsulosin plus a combination of boldine, P. niruri, and Ononis spinosa. The stone expulsion rate was 84.8% in the combination group versus 52.5% in the tamsulosin‑alone group. The combination group also had shorter expulsion time (16.3 vs 19.3 days) and less need for analgesics.

3. For stone prevention (with potassium and magnesium citrates)

A prospective study evaluated a food supplement containing P. niruri and Chrysanthellum americanum in association with potassium and magnesium citrates for recurrent stone formers. The supplement improved quality of life, reduced symptomatic episodes, and lowered the prevalence of asymptomatic bacteriuria.

4. Limitations of the evidence

Despite these positive findings, the evidence has limitations. A 2025 systematic review noted that while P. niruri appears safe and may improve stone‑free rates after ESWL, the clinical significance of the benefit is modest, and high‑quality randomised trials are still needed. Additionally, most studies used P. niruri as an adjunct to standard treatment, not as a standalone therapy.

Dosage and forms (capsules, tea, tincture, extract)

Phyllanthus niruri is available in several forms. There is no standardised dosage, but common regimens based on clinical studies include:

In the ESWL adjuvant study, patients received 2g of P. niruri extract daily for at least 3 months. In the medical expulsion therapy study, the combination product was taken for up to 4 weeks.

Duration: For prevention, 3‑6 months of continuous use is typical. For acute passage, up to 4‑8 weeks. Always consult your doctor before starting any herbal supplement.

Safety profile and potential side effects

Multiple studies have confirmed that Phyllanthus niruri is generally safe when used as directed. A 2025 systematic review noted that evidence consistently supports P. niruri’s long‑term safety, confirmed by serial measurements of serum electrolytes and liver function. In the ESWL adjuvant study, no side effects were recorded with P. niruri therapy.

Potential side effects (rare) include:

• Mild gastrointestinal upset (nausea, loose stools)
• Dizziness (rare)
• Allergic reactions (rare)

Contraindications and precautions:

• Pregnancy and breastfeeding: Safety not established. Avoid.
• Diabetes: The herb may lower blood sugar. Monitor glucose levels if taking antidiabetic medications.
• Blood pressure medications: Possible additive hypotensive effect.
• Blood thinners (warfarin, aspirin): Theoretical interaction; limited data.
• Potassium levels / heart conditions: Use with caution.
• Chronic kidney disease (CKD stages 3‑5): Consult your nephrologist before use.

Interactive FAQ – Kidney stone plant (Phyllanthus niruri)

Disclaimer: This information is for educational purposes. Phyllanthus niruri is not a substitute for evidence‑based medical treatment. If you have a stone >6mm, fever, or hydronephrosis, seek immediate urological care at Vivekananda Hospital.